Skip to main content

Age Expansion Indication for Cibinqo Clinical Prior Authorization Criteria Effective May 31, 2023

Last updated on 5/12/2023

On May 31, 2023, the Texas Health and Human Services Commission (HHSC) will implement the new age expansion indication for Cibinqo (abrocitinib) to update the Cibinqo clinical prior authorization criteria. The age expansion will include adolescents 12 through 18 years of age whose atopic dermatitis is not adequately controlled with other systemic drugs, including biologics, or when other therapies are not advised. The U.S. Food and Drug Administration recently approved this age expansion.

The cytokine and CAM antagonist prior authorization is optional for managed care organizations.

Contact with comments or questions.